BioSpace News Archive

May 18, 2020 12:00 UTC BOTHELL, Wash.--( BUSINESS WIRE )-- Seattle Genetics, Inc. (Nasdaq:SGEN) today announced highlights from 12 presentations showcasing its research and development portfolio of novel targeted therapies and antibody-drug conjugate (ADC) technology advances and innovation will be presented at the American Association for Cancer Research (AACR) Virtual Annual Meeting II being held June 22-24, 2020. Registration information to attend the virtual sessions can be

Aptorum Group Limited, a biopharmaceutical company focused on the development of novel therapeutics to address global unmet medical needs, announced President and Executive Director Darren Lui will share insight into the company’s recent developments and upcoming milestones during an investor webinar on Tuesday, May 19, 2020 at 4:00 p.m. ET.

Aegea Biotechnologies, Inc. ( “Aegea”) ( www.aegeabiotech.com), a biotechnology company focusing on the development and commercialization of next generation nucleic acid clinical diagnostic technologies, announces the issuance of 7 additional key US patents related to its core next generation nucleic acid clinical diagnostic technologies, including applications related to COVID-19 diagnostic testing under the c

As further evidence of the strong industry response to a potential new paradigm in the treatment of cancer, Varian (NYSE: VAR) today announced that Proton Therapy Pte., Ltd. ( http://www.proton.sg/ ) in Sin

AnPac Bio-Medical Science Co., Ltd., a biotechnology company with operations in China and the United States focused on early cancer screening and detection, announced that it has filed its annual report on Form 20-F for the fiscal year ended December 31, 2019 with the U.S. Securities and Exchange Commission on May 15, 2020.

Orexo, a Swedih pharmaceutical company focused on improved pharmaceuticals and digital therapies, announced that it will partner with Lyfebulb, a patient empowerment platform, to work with substance abuse patients to identify unmet needs made more acute by the pandemic,

JHL Biotech, Inc. today announced that the first group of subjects has been randomized and dosed last week in the company’s Australian Phase I Clinical Trial of JHL1266 in healthy subjects. The Three-A

Phase II clinical trial expected to be conducted at multiple centers in the United States, including three Mayo Clinic sites under the leadership of Andrew D. Badley, M.D., Enterprise Chair of COVID-19 Task Force Randomized, double blind, placebo-controlled clinical trial to be conducted in adults with COVID-19 who are hospitalized and either require supplemental oxygen or are on non-invasive ventilation or high flow oxygen devices BioS

ChemoCentryx, Inc., (NASDAQ: CCXI) and Vifor Fresenius Medical Care Renal Pharma (VFMCRP) today announced topline data from a forty-six (46) patient Phase II dose-ranging trial in the orphan kidney disorder, primary Focal Segmental Glomerulosclerosis (FSGS). The LUMINA-1 trial tested CCX140, an orally-administered selective inhibitor of the chemokine receptor known as CCR2, in primary FSGS subjects. In the study, CCX140

Independent Data Monitoring Committee (DMC) to Review and Evaluate Patient Safety and Efficacy Data for Pivotal Phase 3 Trial of Galinpepimut-S in Patients with Acute Myeloid Leukemia in Second Remission Moshe Talpaz, M.D., Associate Director of Translational Research and Associate Chief of the Division of Hematology/Oncology at the University of Michigan Comprehensive Cancer Center to serve as DMC Chair Thomas Fleming, Ph.D., Professor and former biostatistics department chair of the